Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
127 hedge funds and large institutions have $741M invested in Genomic Health, Inc. in 2016 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 59 increasing their positions, 32 reducing their positions, and 14 closing their positions.
84% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 32
4% less funds holding
Funds holding: 132 → 127 (-5)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
29% less capital invested
Capital invested by funds: $1.04B → $741M (-$300M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$17.3M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$12.8M |
| 3 |
CAM
Cortina Asset Management
Milwaukee,
Wisconsin
|
+$5.52M |
| 4 |
Renaissance Technologies
New York
|
+$4.29M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$3.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$28.5M |
| 2 |
Millennium Management
New York
|
-$3.59M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$3.56M |
| 4 |
ZDA
Zweig-DiMenna Associates
New York
|
-$3.3M |
| 5 |
CC
Casdin Capital
New York
|
-$3.02M |
GHDX Hedge Fund Activity: Q1 2016 in Review
127 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q1 2016, worth a combined $741M — down 29% from $1.04B a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of GHDX and 10 opened new positions — a net loss of 4 holders — while 32 trimmed existing stakes and 59 added.
The largest buyer was Loomis, Sayles & Company, opening a new position worth an estimated $17.3M. The largest seller was Deerfield Management, exiting entirely with an estimated $28.5M sold.
- 127 institutional investors held Genomic Health, Inc. (GHDX) as of Q1 2016, down from 132 in Q4 2015.
- Funds reported $741M of Genomic Health, Inc. stock for Q1 2016, down 29% quarter-over-quarter.
- 10 funds opened new Genomic Health, Inc. positions in Q1 2016 and 14 closed out, a net change of -4 holders.
- The largest Genomic Health, Inc. buyer in Q1 2016 was Loomis, Sayles & Company, an estimated $17.3M added.
- The largest Genomic Health, Inc. seller in Q1 2016 was Deerfield Management, an estimated $28.5M sold.
Based on aggregated 13F filings for Q1 2016.